| Schedule of Segment Financial Information |
The following table summarizes the reportable segment's financial information (in thousands): | | | | | | | | | | | | | | | | Three Months Ended March 31, | | | 2026 | | 2025 | | | | | | | Revenue | $ | 106,677 | | | $ | 93,881 | | | Less: | | | | | Cost of revenue from sale of therapies | (434) | | | (831) | | | External research and development (R&D) expenses: | | | | | | PRAME programs | (21,214) | | | (17,305) | | | | Tebentafusp programs | (8,239) | | | (7,990) | | | | Infectious disease programs | (846) | | | (1,405) | | | All other external clinical and preclinical costs | (8,493) | | | (11,231) | | | | Total external R&D expenses | (38,792) | | | (37,931) | | | | R&D salaries and other employee-related costs | (14,140) | | | (11,043) | | | Selling, general and administrative (SG&A) salaries and other employee-related costs | (13,090) | | | (12,218) | | | Other SG&A expenses | (21,065) | | | (20,672) | | | Other segment (expense) income, net (a) | (6,185) | | | (6,163) | | | Segment and consolidated net income | $ | 12,971 | | | $ | 5,023 | | | | | | | |
(a) Other segment expenses, net includes other internal R&D expenses, share-based compensation expense, R&D tax credits, interest income, interest expense, foreign currency gains, other income, net and income tax expense. |